This invention relates to: a set of ribozymes which comprises at least one ribozyme capable of binding and cleaving Bradeion .alpha. mRNA which corresponds to DNA comprising a nucleotide sequence shown in SEQ ID NO:1, and at least one ribozyme capable of binding to and cleaving Bradeion .beta. mRNA which corresponds to DNA comprising a nucleotide sequence shown in SEQ ID NO:3; a set of vectors comprising ribozymes; a pharmaceutical composition comprising set of vectors; and a method for treating a subject with a cancer using set of vectors.